Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06493240Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in rectal cancer, sponsored by Peking University People's Hospital. Started Jan 2023; status: completed.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06493240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493240.